In brief ThermoEnergy Corp is to acquire CASTion Corp, a supplier of wastewater treatment and chemistry recovery systems. CASTion will become a wholly-owned subsidiary of ThermoEnergy, retaining its name. “This acquisition serves a dual purpose for the company – it is both a strategic market move as well as a growth vehicle for the combined companies,” said Andrew Melton, ThermoEnergy’s CFO. “The acquisition of CASTion is linked directly to enhancing ThermoEnergy’s core business of municipal and industrial wastewater treatment and its ability to capture and maintain market share,” added Dennis C. Cossey, chairman and CEO of ThermoEnergy. www.thermoenergy.com Yosef Katz has resigned as CEO of Amiad. Katz, who managed the company since 1998, is stepping down for personal reasons and will stay on as CEO until a replacement is appointed and a smooth handover can take place. Yosef has agreed to remain on the Board as a non-executive director of the Company. “We would like to thank Yosef for his tremendous contribution to the company over the last nine years,” said Avi Heifetz, Chairman of Amiad. “He has been an inspiration to everyone at the company and we wish him well for the future. He leaves the company strong and stable and, as we stated at the time of our full year results in March, business is progressing well. We are commencing the search for a new CEO who, together with the rest of the current management team, will be able to take the Company to the next level.”
Filtration+Separation June 2007
GE Healthcare develops biopharm segment GE Healthcare has acquired Wave Biotech LLC, a supplier of disposable manufacturing technologies for the biopharmaceutical industry. Financial terms were not disclosed. GE says that the acquisition of Wave Biotech LLC, including its subsidiary Wave Europe Pvt. Ltd, will allow GE Healthcare to expand its offering of products and services for the manufacture of biopharmaceuticals. Wave Biotech develops and manufactures bioreactors designed to replace stainless steel
tanks and piping by eliminating the need for cleaning and validating between batches. The equipment is already in use in over three hundred companies worldwide and Wave Biotech single use bioreactors are also increasingly being used to enable the manufacture of patientspecific cell and gene therapy products, GE says. “The combination of GE Healthcare and Wave Biotech will allow us to expand into new applications and to create a broad offering of added value tools and services for biopharmaceutical
manufacture,” said Ann O’Hara, general manager of GE Healthcare’s BioProcess business. “Our customers will benefit greatly from the global presence and the R&D resources that GE Healthcare brings to the table,” said Dr Vijay Singh, President and founder of Wave Biotech. “The integration of single-use cell culture with GE Healthcare’s existing filtration and downstream operations will provide a host of new disposable solutions to this growing industry.” www.gehealthcare.com
ASHRAE to combine air filter testing standards ASHRAE has set up a proposed addendum open for public comment to combine ASHRAE’s two standards on air filter testing. Combining standards 52.1, Gravimetric and Dust Spot Procedures for Testing Air Cleaning Devices Used in General Ventilation for Removing Particulate Matter, and 52.2, Method of Testing General Ventilation Air-Cleaning Devices for Removal Efficiency by Particle Size, would have several benefits for users, say Monroe Britt and James Hanley, chairs of the Standard 52.1 and 52.2 committees. “One benefit would be having a single ASHRAE test standard for determining the filtration efficiency of HVAC filters,” Hanley said. “This would reduce
ASHRAE’s proposed standards for HVAC could improve air filter efficiency.
the number of tests needed on a filter. Currently, many filters are run twice, once for Standard 52.1 and once for Standard 52.2. It also would allow for one test rig to perform all the needed
tests. Existing differences in the test rig requirements between the two standards make it difficult for one rig to serve both tests.” www.ashrae.org
GL&V sells process division
www.amiad.com On page 30 of the April issue of Filtration+Separation we said that Palas’ new welas®FL system measured particles in concentrations up to 105 P/ cm3. We should have written “in concentrations up to 10E5 P/cm3”. We apologise to Palas for the error.
Groupe Laperrière & Verreault Inc. (GL&V) has signed a conditional agreement with FLSmidth for the latter to acquire GL&V’s process division (GL&V Process), which provides separation technology for the metal and minerals industries and is primarily comprised of the companies Dorr-Oliver Eimco and Krebs.
The agreement is subject to the approval of at least 75% of GL&V’s shareholders. GL&V Process employs some 1,000 people and is expected to post a turnover of approximately CAD 523m (DKK 2.6bn) for the past financial year (1 April 2006 to 31 March 2007).
The acquisition of GL&V Process enables FLSmidth to realise the global growth strategy for its minerals activities, the latter says. The FLSmidth Group’s overall minerals business will in future be marketed under the name of FLSmidth Minerals. www.glv.com